AbbVie ABBV
NYSE ABBV
$295.14 +0.66 (+0.22%)
At close: Nov 13, 2026 · 4:00 PM EST

AbbVie (ABBV) Gains from Sales and Divestitures (2022)

Updated

Analysis

AbbVie (ABBV) Gains from Sales and Divestitures (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn
10 Vertex Pharmaceuticals 136.55 Bn 104.28 Bn 2.91 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 172.00 Mn
API Access

AbbVie Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ABBV&period=max&api_key=YOUR_API_KEY